Skip to content

Publishing of Orion Corporation's Interim Report for January-September 2015 on 27 October 2015


Orion will publish its Interim Report for January-September 2015 on Tuesday, 27 October 2015 approximately at 12:00 noon Finnish time (EET). The release and related presentation material in Finnish and in English will be available on the Group's homepage at promptly after the publishing.

News conference for analysts and media

A news conference for analysts and media will be held on Tuesday 27 October 2015 at 13:30 EET at Hotel Kämp, address Pohjoisesplanadi 29, Helsinki. President and CEO Timo Lappalainen will give a brief presentation in English on the financial review. Questions can be asked after the result presentation.

Participants should be prepared to present a photo ID on request.

Live webcast and conference call

A link to the live webcast will be available at Orion's website

The conference call ID is 955325 and the phone numbers to participate the conference are:

Finland:          +358 (0)9 2313 9202
Sweden:         +46 (0)8 5052 0114
UK:                +44 (0)207 1620 177
USA:              +1 334 323 6203

News conference recordings

A recording of the event in English and a recording of the presentation by the President and CEO in Finnish will be available on the Orion website later the same day.

Silent period

The silent period preceding the publication is ongoing and continues until the disclosure.

Orion Corporation

Timo Lappalainen
President and CEO
Jari Karlson

Contact person:
Tuukka Hirvonen, Communications Manager, IR & Financial Communications
tel. +358 10 426 2721

Orion Corporation

Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs.

Orion's net sales in 2014 amounted to EUR 1,015 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki.